HenryRR, KleinEJ, HanJ, IqbalN: Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study. Diabetes Technol Ther, 2016; 18:677–686.
2.
InzucchiSE, BergenstalRM, BuseJB, et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015; 38:140–149.
3.
GarberAJ, AbrahamsonMJ, BarzilayJI, et al.: Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract, 2016; 22:84–113.
4.
DefronzoRA: Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009; 58:773–795.
5.
WeyerC, BogardusC, MottDM, PratleyRE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest, 1999; 104:787–794.
6.
GilbertMP, PratleyRE: Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med, 2009; 122(6 Suppl):S11–S24.
7.
DeFronzoRA, DavidsonJA, Del PratoS: The role of the kidneys in glucose homeostasis: a new path toward normalizing glycaemia. Diabetes Obes Metab, 2012; 14:5–14.
8.
CampbellJE, DruckerDJ: Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab, 2013; 17:819–837.
9.
MadsbadS: Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab, 2016; 18:317–332.
10.
BodeBW, BrettJ, FalahatiA, PratleyRE: Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother, 2011; 9:423–433.
11.
DaviesM, ChatterjeeS, KhuntiK: The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol, 2016; 8:61–81.
12.
PfefferMA, ClaggettB, DiazR, et al; ELIXA Investigators: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med, 2015; 373:2247–2257.
13.
MarsoSP, DanielsGH, Brown-FrandsenK, et al.; LEADER Steering Committee on behalf of the LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375:311–322.
14.
MarsoSP, BainSC, ConsoliA, et al.: Semiglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016Sept16; doi: 10.1056/NEJMoa1607141.
15.
EganAG, BlindE, DunderK, et al.: Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med, 2014; 370:794–797.
